Category: News

Macrilen (JMV 1843) – a drug developed by our group just got approved by FDA !!!


Macrilen, a revolution in the growth hormone  dose-titration !

MacrilenTM (JMV 1843), conceptualized and synthesized in IBMM, is the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency. It is a novel, orally active small molecule that mimics the ghrelin hormone and stimulates the secretion of growth hormone by activation of the ghrelin receptor. A single ingestion of this compound, followed by titration of growth hormone in the blood, allows the evaluation of growth hormone deficiency. It has been approved by the FDA for the diagnosis of growth hormone deficiency in adults and will be commercialized by Æterna-Zentaris in USA and Canada in 2018. It should find other applications such as treatment of cachexia and we are waiting its approval for the diagnosis in Europe.

New publication on importance of peptide orientation on titanium surface

Congrats to Gilles and Nicolas for their new paper!

Our team demonstrates for the first time that the controlled orientation of silylated hybrid-temporins on titanium surfaces could improve antibacterial activity of the material. In collaboration with Dr Vincent Humblot (UMR CNRS 7197, Paris) and Pr Ahmad Mehdi (Institute Charles Gerhardt, Montpellier), we designed 5 analogues of the antimicrobial peptide temporin SHa and studied the impact of the site-specific and orientation of the peptides on the antibacterial activity of the grafted titanium device. This work is published in J. Mater. Chem. B (DOI: 10.1039/c8tb00051d).

Julie Martin – Presentation at Belgium Peptide Meeting Bruxelles 2018

Congratulation Julie!

Last week Julie participated in the fourth Belgian Peptide Group Meeting (BPGM), for its 2018 version, taking place in Bruxelles Wednesday 28th of February and Thursday 1st of March. Almost 120 people coming for all around the world came to share their knowledge and on-going research project in the field of peptide. She also had the opportunity to present her own work, about the synthesis of new hybrid monomer leading to peptide-modified silicone, during a 20min oral communication.